Palopegteriparatide

Does Palopegteriparatide work?

Yes, in a controlled trial of 84 adults.

Approval rests on the PaTHway phase 3 trial, a randomized, double-blind, placebo-controlled study in 84 adults with hypoparathyroidism, in which the composite endpoint of normal calcium without conventional therapy was met by a large majority on drug and almost none on placebo. The randomized period was short at 26 weeks; the open-label extension, published out to 3.5 years in 2026, carries the long-term story. ¹²³

PaTHway randomized 84 adults with long-term hypoparathyroidism, about three to one. They got palopegteriparatide or placebo for 26 weeks. Both groups kept their usual therapy, which was then tapered. The main measure combined several goals. Blood calcium had to be normal. Patients had to stop active vitamin D and therapeutic calcium doses. They could not need more study drug in the final weeks. About 79 percent of patients on palopegteriparatide met it. About 5 percent on placebo did. Urinary calcium is chronically high on usual therapy and damages kidneys. On the drug, it fell into the normal range. Patient-reported symptom and quality of life scores also improved. ¹

The label sums up the open-label extension of PaTHway. Among patients first randomized to the drug, 64% kept normal calcium at week 52. They also stayed free of active vitamin D and therapeutic calcium. At week 78, 66% did, when dose increases were allowed. ²

Read the full Palopegteriparatide page

Reference information only, not medical advice. Drawn from the Palopegteriparatide article, fact-checked against the cited sources. No dosing anywhere on this site.